Global Phenylketonuria Market Expected to Reach XX Million by 2025 growing at CAGR of XX%
According to a new report published by Reports Monitor titled, “phenylketonuria Market by treatment, route of administration and End-user: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the global phenylketonuria Market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025. North America is expected to grow lucratively maintain leading position throughout the forecast period.
Phenylketonuria is the medical condition that causes amino acid build-up of phenylalanine owing to mutation in the PAH gene that is culpable for production of the enzyme called phenylalanine hydroxylase. The dearth of the enzyme or inadequacy reduces the breakdown & conversion of the phenylalanine into tyrosine that is needed to create neurotransmitters such as norepinephrine, epinephrine and dopamine. This condition results into gradual accumulation of the amino acid inducing phenylketonuria condition. The disease in hereditary and symptoms include mental disorder, intellectual defect, seizures and brain damage. Treatment measures include Lofenalac formulated consumption and low protein content diet.
Growing number of congenital metabolic disease, increased healthcare expenditure and diagnostic technological development leads the market to grow massively. Moreover, large number of clinical trials performed, response of the population group and high amount of drugs in pipeline along with supportive actions deployed by government are the factors lifting the growth of the market. Notwithstanding, rigorous and austere guidelines followed by FDA and time required for the approval for new product are likely to constrain the market growth in coming times.
Phenylketonuria being hereditary disease and having no permanent cure provides lucrative opportunities to the players to introduce abiding treatment options.
Key questions Answered: • What will the market size and the growth rate be in 2025? • What are the key factors driving the global cervical cancer diagnostic testing market? • Who are the key vendors in the global cervical cancer diagnostic testing market? • What are the challenges to market growth? • What is the trending factors influencing the market shares of the Americas, APAC, and EMEA?
Key Players profiled in the market are: Nutricia, Abbott, American Gene TechnologiesInternational Inc., BioMarin Pharmaceutical Inc., Biomarin, Vitaflo, Daiichi Sankyo Company, Dimension Therapeutics, Inc., Codexis, Inc., Synthetic Biologics, Inc., SOM Innovation Biotech SL, Erytech Pharma SA
We at Garner Insights.com provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.